A new method to detect cancer DNA in blood samples.
Official title: Simple and Accessible Microfluidic Platform for Single Molecule Sequence Profiling of Tumor-derived DNA within Liquid Biopsies
Funded at Hypermelt, LLC · NIH-10699214 · Data updated 2026-11-12
This study is testing a new, gentle way to check for cancer by looking at DNA from blood samples, which could help catch the disease earlier and make it easier for patients to get tested.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hypermelt, LLC NIH-funded |
| Lab location | 1 site (White Marsh, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $275,721 |
| NIH project number | 1R43CA281570-01 |
| Project ID | NIH-10699214 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for cancer or those with early-stage cancer who may benefit from non-invasive testing methods.
✕Less likely to help
Patients with advanced-stage cancer or those who do not have detectable tumor-derived DNA in their blood may not benefit from this research.
What this research studies
This research focuses on developing a microfluidic platform that can analyze tumor-derived DNA from liquid biopsies, such as blood samples. By using this innovative technology, the goal is to identify specific molecular biomarkers associated with cancer, which can help in early detection. The approach is minimally invasive, making it easier for patients to undergo testing compared to traditional biopsy methods. The research aims to improve the sensitivity and accuracy of detecting cancer-related DNA, potentially leading to better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier cancer detection, improving survival rates and treatment outcomes for patients.
How similar studies have gone: Previous research has shown promise in using liquid biopsies for cancer detection, indicating that this approach could be a significant advancement in cancer diagnostics.
Where this research is happening
-
Hypermelt, LLC
White Marsh, United States Active
Researchers
- Principal investigator: O'keefe, Christine — Hypermelt, LLC
- Study coordinator: O'keefe, Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.